GlassScriptPhysician profile
Shanthi M Colaco
NPI 1144482167
$8,031.63
in general payments reported to CMS, 2019-2025
27 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $604 · 2021: $1,659 · 2022: $757 · 2023: $810 · 2024: $1,491 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,469.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,393.58 | 2019-2025 | Aklief, Epsolay, Oracea |
| Sun Pharmaceutical Industries INC. | $717.77 | 2019-2025 | Winlevi |
| Genzyme Corporation | $704.56 | 2020-2025 | |
| Pfizer INC. | $667.21 | 2019-2025 | |
| Abbvie INC. | $505.42 | 2021-2025 | Botox, Skyrizi |
| Allergan, INC. | $495.36 | 2019-2022 | |
| Revance Therapeutics, INC. | $417.20 | 2025 | Daxxify |
| Leo Pharma INC. | $395.53 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $351.04 | 2022-2025 | Tremfya, Simponi Aria |
| Mayne Pharma Commercial LLC | $334.82 | 2019-2025 | |
| Journey Medical Corporation | $273.94 | 2020-2025 | |
| Incyte Corporation | $233.56 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $203.39 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $189.82 | 2020-2024 | Dupixent |
| Botanix Sb INC | $183.18 | 2025 | Sofdra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $145.26 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $144.12 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Novartis Pharmaceuticals Corporation | $118.18 | 2019-2024 | |
| Ucb, INC. | $106.39 | 2024-2025 | Bimzelx |
| Celgene Corporation | $89.34 | 2019 | |
| Merz North America, INC. | $77.10 | 2021-2024 | |
| Dermavant Sciences, INC. | $75.08 | 2024 | Vtama |
| Epi Health, LLC | $52.98 | 2021 | |
| Amgen INC. | $48.53 | 2021-2024 | Otezla |
| Almirall LLC | $48.38 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $44.89 | 2019 | |
| Vyne Pharmaceuticals INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanthi Colaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.